Vilobelimab: meta-analysis of COVID-19 studies

All studies   Mortality   Serious outcomes   RCTs   RCT mortality   Peer-reviewed   All outcomes  
Meta-analysis1 study · 368 patientsc19early.org

Vilobelimab for COVID-19

Serious outcome risk
Vilobelimab
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)26%
Mortality (1)26%
RCTs (1)26%
Late (1)26%
00.511.5+
← Vilobelimab
reduces riskIncreased
risk →
c19early.org
October 2026

Vilobelimab COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Vlaar (DB RCT)26%0.74 · 0.52–1.04death177 (n)191 (n)PANAMOVentilated patients
Late treatment26%0.74 · 0.53–1.04177 (n)191 (n)26% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.082
All studies26%0.74 · 0.53–1.04177 (n)191 (n)26% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.08200.511.52+
Rotate screen for more detailsIncrease width for more details
← Vilobelimab
reduces riskVilobelimab
increases risk →
c19early.org
October 2026

Vilobelimab COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Vlaar (DB RCT)26%0.74 · 0.52–1.04177 (n)191 (n)PANAMOVentilated patients
Late treatment26%0.74 · 0.53–1.04177 (n)191 (n)26% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.082
All studies26%0.74 · 0.53–1.04177 (n)191 (n)26% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.08200.511.52+
Rotate screen for more detailsIncrease width for more details
← Vilobelimab
reduces riskVilobelimab
increases risk →
c19early.org
October 2026

Vilobelimab COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Vlaar (DB RCT)26%0.74 · 0.52–1.04death177 (n)191 (n)PANAMOVentilated patients
Late treatment26%0.74 · 0.53–1.04177 (n)191 (n)26% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.082
All studies26%0.74 · 0.53–1.04177 (n)191 (n)26% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.08200.511.52+
Rotate screen for more detailsIncrease width for more details
← Vilobelimab
reduces riskVilobelimab
increases risk →
c19early.org
October 2026

Vilobelimab COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Vlaar (DB RCT)26%0.74 · 0.52–1.04death177 (n)191 (n)PANAMOVentilated patients
Late treatment26%0.74 · 0.53–1.04177 (n)191 (n)26% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.082
All studies26%0.74 · 0.53–1.04177 (n)191 (n)26% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.08200.511.52+
Rotate screen for more detailsIncrease width for more details
← Vilobelimab
reduces riskVilobelimab
increases risk →
c19early.org
October 2026

Vilobelimab COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Vlaar (DB RCT)26%0.74 · 0.52–1.04177 (n)191 (n)PANAMOVentilated patients
Late treatment26%0.74 · 0.53–1.04177 (n)191 (n)26% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.082
All studies26%0.74 · 0.53–1.04177 (n)191 (n)26% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.08200.511.52+
Rotate screen for more detailsIncrease width for more details
← Vilobelimab
reduces riskVilobelimab
increases risk →
c19early.org
October 2026

Vilobelimab COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Vlaar (DB RCT)26%0.74 · 0.52–1.04death177 (n)191 (n)PANAMOVentilated patients
Late treatment26%0.74 · 0.53–1.04177 (n)191 (n)26% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.082
All studies26%0.74 · 0.53–1.04177 (n)191 (n)26% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.08200.511.52+
Rotate screen for more detailsIncrease width for more details
← Vilobelimab
reduces riskVilobelimab
increases risk →